Lipella Pharmaceuticals re-signs manufacturing collab with Cook MyoSite
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2025
0mins
Should l Buy ?
Manufacturing Collaboration Renewal: Lipella Pharmaceuticals has renewed its manufacturing collaboration agreement with Cook MyoSite to enhance Chemistry, Manufacturing and Control (CMC) documentation for their clinical products LP-10 and LP-310.
CEO Statement: Dr. Jonathan Kaufman expressed satisfaction with the renewed partnership, highlighting Cook MyoSite's reputation for high-quality manufacturing as crucial for Lipella's advancing clinical pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
